Market Closed -
Toronto S.E.
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
11.92
CAD
|
+1.10%
|
|
-0.17%
|
+12.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
10,545
|
7,385
|
9,921
|
2,273
|
2,929
|
3,194
|
-
|
-
|
Enterprise Value (EV)
1 |
33,196
|
29,494
|
30,456
|
2,273
|
2,929
|
23,099
|
21,523
|
3,194
|
P/E ratio
|
-5.89
x
|
-13.2
x
|
-10.5
x
|
-10.1
x
|
-4.95
x
|
13.2
x
|
8.46
x
|
7.38
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.23
x
|
0.92
x
|
1.18
x
|
0.28
x
|
0.33
x
|
0.34
x
|
0.34
x
|
0.32
x
|
EV / Revenue
|
3.86
x
|
3.67
x
|
3.61
x
|
0.28
x
|
0.33
x
|
2.46
x
|
2.28
x
|
0.32
x
|
EV / EBITDA
|
9.3
x
|
8.95
x
|
8.77
x
|
0.75
x
|
0.97
x
|
7.1
x
|
6.56
x
|
0.9
x
|
EV / FCF
|
27
x
|
36.5
x
|
26.3
x
|
-2.4
x
|
3.58
x
|
15.2
x
|
13.7
x
|
-
|
FCF Yield
|
3.71%
|
2.74%
|
3.8%
|
-41.6%
|
27.9%
|
6.58%
|
7.32%
|
-
|
Price to Book
|
9.92
x
|
13.8
x
|
-
|
-
|
-
|
-4.92
x
|
-21.8
x
|
-
|
Nbr of stocks (in thousands)
|
352,431
|
355,053
|
359,331
|
361,868
|
365,195
|
366,673
|
-
|
-
|
Reference price
2 |
29.92
|
20.80
|
27.61
|
6.280
|
8.020
|
8.710
|
8.710
|
8.710
|
Announcement Date
|
2/19/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,601
|
8,027
|
8,434
|
8,124
|
8,757
|
9,386
|
9,453
|
9,909
|
EBITDA
1 |
3,571
|
3,294
|
3,472
|
3,022
|
3,014
|
3,252
|
3,281
|
3,547
|
EBIT
1 |
3,226
|
2,959
|
2,951
|
2,775
|
2,808
|
3,045
|
3,054
|
3,267
|
Operating Margin
|
37.51%
|
36.86%
|
34.99%
|
34.16%
|
32.07%
|
32.44%
|
32.31%
|
32.97%
|
Earnings before Tax (EBT)
1 |
-1,837
|
-934
|
-1,024
|
-129
|
-390
|
313.8
|
438.4
|
522.1
|
Net income
1 |
-1,788
|
-560
|
-948
|
-225
|
-592
|
336.2
|
381.2
|
431.7
|
Net margin
|
-20.79%
|
-6.98%
|
-11.24%
|
-2.77%
|
-6.76%
|
3.58%
|
4.03%
|
4.36%
|
EPS
2 |
-5.080
|
-1.580
|
-2.640
|
-0.6200
|
-1.620
|
0.6575
|
1.030
|
1.180
|
Free Cash Flow
1 |
1,231
|
809
|
1,157
|
-946
|
817
|
1,521
|
1,576
|
-
|
FCF margin
|
14.31%
|
10.08%
|
13.72%
|
-11.64%
|
9.33%
|
16.2%
|
16.67%
|
-
|
FCF Conversion (EBITDA)
|
34.47%
|
24.56%
|
33.32%
|
-
|
27.11%
|
46.76%
|
48.02%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
452.33%
|
413.29%
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/19/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2,111
|
2,196
|
1,918
|
1,967
|
2,046
|
2,193
|
1,944
|
2,167
|
2,238
|
2,408
|
2,149
|
2,339
|
2,406
|
2,485
|
2,235
|
EBITDA
1 |
885
|
909
|
732
|
701
|
766
|
823
|
588
|
727
|
830
|
869
|
714
|
793
|
840.2
|
869.6
|
791.9
|
EBIT
1 |
755
|
773
|
618
|
587
|
668
|
771
|
494
|
651
|
747
|
812
|
707.7
|
753.5
|
784
|
791.9
|
-
|
Operating Margin
|
35.77%
|
35.2%
|
32.22%
|
29.84%
|
32.65%
|
35.16%
|
25.41%
|
30.04%
|
33.38%
|
33.72%
|
32.93%
|
32.22%
|
32.58%
|
31.87%
|
-
|
Earnings before Tax (EBT)
1 |
216
|
21
|
-82
|
-129
|
439
|
-357
|
-136
|
79
|
-326
|
-7
|
-19.85
|
63.9
|
115
|
149.4
|
71.7
|
Net income
1 |
188
|
69
|
-69
|
-145
|
399
|
-410
|
-201
|
26
|
-378
|
-39
|
-106
|
-10
|
59
|
96
|
-
|
Net margin
|
8.91%
|
3.14%
|
-3.6%
|
-7.37%
|
19.5%
|
-18.7%
|
-10.34%
|
1.2%
|
-16.89%
|
-1.62%
|
-4.93%
|
-0.43%
|
2.45%
|
3.86%
|
-
|
EPS
2 |
0.5200
|
0.1900
|
-0.1900
|
-0.4000
|
1.100
|
-1.130
|
-0.5500
|
0.0700
|
-1.030
|
-0.1100
|
-0.1150
|
0.0650
|
0.1800
|
0.2550
|
0.1400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/23/22
|
5/10/22
|
8/9/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
22,651
|
22,109
|
20,535
|
-
|
-
|
19,905
|
18,330
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
6.343
x
|
6.712
x
|
5.914
x
|
-
|
-
|
6.12
x
|
5.587
x
|
-
|
Free Cash Flow
1 |
1,231
|
809
|
1,157
|
-946
|
817
|
1,521
|
1,576
|
-
|
ROE (net income / shareholders' equity)
|
82.1%
|
179%
|
-
|
-
|
-665%
|
300%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
4.7%
|
4.39%
|
-3.14%
|
-
|
-
|
1%
|
1.5%
|
-
|
Assets
1 |
-38,051
|
-12,757
|
30,201
|
-
|
-
|
33,624
|
25,414
|
-
|
Book Value Per Share
2 |
3.020
|
1.510
|
-
|
-
|
-
|
-1.770
|
-0.4000
|
-
|
Cash Flow per Share
2 |
4.260
|
3.130
|
3.970
|
-2.010
|
2.830
|
4.450
|
3.970
|
-
|
Capex
1 |
270
|
302
|
269
|
218
|
215
|
254
|
217
|
-
|
Capex / Sales
|
3.14%
|
3.76%
|
3.19%
|
2.68%
|
2.46%
|
2.71%
|
2.29%
|
-
|
Announcement Date
|
2/19/20
|
2/24/21
|
2/23/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
8.71
USD Average target price
10.07
USD Spread / Average Target +15.63% Consensus |
1st Jan change
|
Capi.
|
---|
| +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|